natgillin/translations-raw huggingface dataset:
No data on residues in milk following oral administration were available and no data that would allow extrapolation of residue concentrations from plasma concentrations following oral use were available.
Na voljo niso bili niti podatki o ostankih v mleku po peroralnem dajanju niti podatki, ki bi omogočili ekstrapolacijo koncentracij ostankov iz plazemskih koncentracij po peroralni uporabi.
Cydectin Triclamox 1 mg/ml + 50 mg/ml Solución Oral Para Ovino
Cydectin Triclamox 1 mg/ml + 50 mg/ml Solución Oral Para Ovino triklabendazol moksidektin peroralna raztopina
Mectaject Plus Clorsulon Ivermectin subcutaneous Cattle
Mectaject Plus klorsulon ivermektin
Defining a safe concentration for closantel in milk - cattle
Določanje varne koncentracije klozantela v mleku - govedo
It is therefore considered that the only acceptable use of triclabendazole in goats intended for production of milk for human consumption would involve administration to young animals before the first pregnancy and at least 1 year before the first lambing.
Zato se šteje, da je edina sprejemljiva uporaba triklabendazola pri kozah, katerih mleko je namenjeno prehrani ljudi, dajanje mladim živalim pred prvo brejostjo in vsaj 1 leto pred prvo kotitvijo.
Cydectin Triclamox 1 mg/ml + 50 mg/ml orale oplossing voor schapen
Cydectin Triclamox 1 mg/ml + 50 mg/ml orale oplossing voor schapen triklabendazol moksidektin peroralna raztopina
Cydectin TriclaMox 1 mg/ml + 50 mg/ml Oral Solution for Sheep
Cydectin TriclaMox 1 mg/ml + 50 mg/ml Oral Solution for Sheep triklabendazol moksidektin peroralna raztopina
Cattle, Sheep, Goats
Seponver klozantel govedo, ovce
It is concluded that the only acceptable use of closantel in ewes intended for production of milk for human consumption would involve administration to young animals before the first pregnancy and at least 1 year before the first lambing.
Sledi zaključek, da je edina sprejemljiva uporaba klozantela pri ovcah, katerih mleko je namenjeno prehrani ljudi, dajanje mladim živalim pred prvo brejostjo in vsaj 1 leto pred prvo jagnjitvijo.
Not authorised for use in goats producing milk for human consumption including during the dry period.
Ni dovoljena uporaba pri kozah, katerih mleko je namenjeno prehrani ljudi, vključno z dobo presušitve.
Seponver
Ciper
Triclaben 10% Triclabendazole 100 mg/ml
Triclaben 10% triklabendazol
IVOMEC PLUS Clorsulon Ivermectin subcutaneous Cattle
Ivomec Plus klorsulon ivermektin
Cydectine Triclamox 1 mg/ml + 50 mg/ml Solution Buvable Pour Ovins
Cydectine Triclamox 1 mg/ml + 50 mg/ml Solution Buvable Pour Ovins triklabendazol moksidektin peroralna raztopina
Flukiver Combi vet
Flukiver Combi klozantel mebendazol
Endex 19,5% Triclabendazole 12 g/100 ml
Endex 19.5 % triklabendazol levamizol
25 mg/ml 28 mgml
25 mg/ml 28 mgml govedo, ovce
Triclanil 10% Triclabendazole 100 mg/ml
Triclanil 10% triklabendazol
Triclanil 5% Triclabendazole 50 mg/ml
Triclanil 5% triklabendazol
Closamectin Closantel lvermectin subcutaneous Cattle
Closamectin Pour-on Solution for Cattle klozantel ivermektin kožni poliv dajanje kožnega poliva
After the Commission decision the Member State competent authorities, in liaison with the reference Member State, will update the product information as required.
Po odločitvi Komisije bodo pristojni organi v državah članicah skupaj z referenčno državo članico v skladu z zahtevami posodobili podatke o zdravilu.
The valid summary of product characteristics, labelling and package leaflet are the final versions achieved during the Coordination group procedure.
Veljavni povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo so zadnje različice, ki so bile pripravljene v postopku koordinacijske skupine.
Note: This SmPC, labelling and packages leaflet is the version valid at the time of Commission decision.
Opomba: Ta različica povzetka glavnih značilnosti zdravila, označevanja in navodila za uporabo je različica, ki je veljavna v času sprejetja odločitve Komisije.
Therefore, this SmPC, labelling and package leaflet may not necessarily represent the current text.
Tako ta povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo morda ne odražajo trenutnega besedila.
The Mutual Recognition Procedure (UK/V/0145/001/II/007) started on 30 January 2009.
Postopek medsebojnega priznavanja (UK/V/0145/001/II/007) se je začel dne 30. januarja 2009.
The final opinion was converted into a Decision by the European Commission on 16 August 2010.
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 16. avgusta 2010.
The application was submitted in the framework of Article 6 of Commission Regulation (EC) No 1084/2003, where the Reference Member State was the United Kingdom and the Concerned Member States were Austria, Belgium, Germany, Greece, Spain, France, Ireland, Italy, Luxembourg, the Netherlands and Portugal.
Vloga je bila predložena v okviru člena 6 Uredbe Komisije (ES) št. 1084/2003, pri čemer je bila referenčna država članica Združeno kraljestvo, zadevne države članice pa Avstrija, Belgija, Nemčija, Grčija, Španija, Francija, Irska, Italija, Luksemburg, Nizozemska in Portugalska.
Article 6(12) of Commission Regulation (EC) No 1084/2003.
Člen 6(12) Uredbe Komisije (ES) št. 1084/2003.
Written explanations were provided by the marketing authorisation holder on 15 January 2010 and supplementary information was submitted on 20 April
Imetnik dovoljenja za promet z zdravilom je dne 15. januarja 2010 podal razlago v pisni obliki, dodatne informacije pa je predložil dne 20. aprila 2010.
Porcilis PRRS is an immunological veterinary medicinal product containing the Porcine Reproductive and Respiratory Syndrome (PRRS) virus.
Zdravilo Porcilis PRRS je imunološko zdravilo za uporabo v veterinarski medicini, ki vsebuje virus prašičjega reprodukcijskega in respiratornega sindroma (PRRS).
On 2 October 2009 the United Kingdom, referred the matter to the Agency under Article 39 of Directive 2001/82/EC as amended by reference to Article 6(12) of Regulation (EC) No 1084/2003 due to concerns raised by Spain relating to the quality and efficacy of the simultaneous administration of Porcilis PRRS with Porcilis M Hyo.
2. oktobra 2009 je Združeno kraljestvo zadevo napotilo na agencijo v skladu s členom 39 Direktive 2001/82/ES, kakor je bila spremenjena, s sklicevanjem na člen 6(12) Uredbe (ES) št. 1084/2003 zaradi zadržkov, ki jih je imela Španija glede kakovosti in učinkovitosti sočasne uporabe zdravil Porcilis PRRS in Porcilis M Hyo.
The product is indicated for use in breeding and finishing pigs from 2 weeks of age.
Zdravilo je indicirano za uporabo pri prašičih za vzrejo in zakol od 2. tedna starosti.
Based on the rapporteurs' assessment of the currently available data, the CVMP adopted, on 19 May 2010, an opinion recommending that the variation application applied for the veterinary medicinal product Porcilis PRRS satisfies the criteria for approval.
Na podlagi poročevalčevih ocen trenutno razpoložljivih podatkov je CVMP dne 19. maja 2010 sprejel mnenje, v katerem je priporočil, da vloga za spremembo za zdravilo Porcilis PRRS za uporabo v veterinarski medicini izpolnjuje kriterije za odobritev.
During the procedure Dr C. Muñoz Madero replaced Dr C. Rubio Montejano as rapporteur.
Med postopkom je dr. C. Muńoz Madero zamenjala dr. C. Rubio Montejano v vlogi poročevalke.
The Committee appointed Dr C. Rubio Montejano as rapporteur and Dr A.M. Brady as co-rapporteur.
Odbor je za poročevalko imenoval dr. C. Rubio Montejano, za soporočevalko pa dr. A. M. Brady.
referral for Porcilis
za zdravilo Porcilis PRRS
The marketing authorisation holder Intervet International B.V. submitted an application for a Type II variation subject to Mutual Recognition Procedure for Porcilis PRRS concerning simultaneous administration with Porcilis M Hyo.
Imetnik dovoljenja za promet z zdravilom, družba Intervet International B.V., je predložil vlogo za spremembo tipa II po postopku z medsebojnim priznavanjem za zdravilo Porcilis PRRS v zvezi s sočasno uporabo z zdravilom Porcilis M Hyo.
Further information on Steglujan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Več informacij o zdravilu Steglujan je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It is used together with diet and exercise in the following patients:
Uporablja se v kombinaciji z dieto in telesno vadbo pri naslednjih bolnikih:
Regarding safety, this was considered in line with that of other medicines of the same class.
Varnost je bila ocenjena kot primerljiva z drugimi zdravili istega razreda.
What measures are being taken to ensure the safe and effective use of Steglujan?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Steglujan?
The European Medicines Agency decided that Steglujan's benefits are greater than its risks and it can be authorised for use in the EU.
Evropska agencija za zdravila je zaključila, da so koristi zdravila Steglujan večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
What is Steglujan and what is it used for?
Kaj je zdravilo Steglujan in za kaj se uporablja?
Why is Steglujan authorised in the EU?
Zakaj je bilo zdravilo Steglujan odobreno v EU?
As for all medicines, data on the use of Steglujan is continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Steglujan stalno spremljajo.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Steglujan have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Steglujan upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
At the start of the studies, patients' HbA1c was above 7.0%.
Na začetku študij je bila raven HbA1c pri bolnikih nad 7,0 %.
What are the risks associated with Steglujan?
Kakšna tveganja so povezana z zdravilom Steglujan?
An overview of Steglujan and why it is authorised in the EU
Pregled zdravila Steglujan in zakaj je odobreno v EU
For more information about using Steglujan, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Steglujan glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
In addition, the results indicated that treatment with Steglujan was associated with a beneficial reduction in body weight.
Poleg tega so rezultati pokazali, da je zdravljenje z zdravilom Steglujan povezano s koristnim zmanjšanjem telesne mase.
What benefits of Steglujan have been shown in studies?
Kakšne koristi zdravila Steglujan so se pokazale v študijah?
In patients whose blood sugar needs further control, the dose can be increased to one 15 mg/100 mg tablet once a day.
Pri bolnikih, pri katerih je treba krvni sladkor še nadalje uravnavati, se odmerek lahko poveča na eno tableto v višini 15 mg/100 mg enkrat dnevno.
The result is a high level of glucose in the blood.
Posledica je visoka raven glukoze v krvi.
• patients who are already taking ertugliflozin and sitagliptin as separate tablets.
• pri bolnikih, ki že jemljejo ertugliflozin in sitagliptin v obliki ločenih tablet.
The most common side effects with Steglujan (which may affect more than 1 in 10 people) are fungal infections of the vagina and other infections of the female reproductive system.
Najpogostejši neželeni učinki zdravila Steglujan (ki se lahko pojavijo pri več kot 1 bolniku od 10) so glivične okužbe nožnice in druge okužbe ženskih spolovil.
Three main studies, involving 1,987 patients showed that Steglujan was effective at lowering blood glucose levels in patients with type 2 diabetes, as measured by the decrease in blood levels of HbA1c (a measure of blood glucose) after 6 months of treatment.
Tri glavne študije, ki so vključevale 1 987 bolnikov, so pokazale, da je zdravilo Steglujan pri bolnikih s sladkorno boleznijo tipa 2 učinkovito pri zniževanju ravni glukoze v krvi, kar so ugotovili glede na znižanje ravni HbA1c v krvi (merilo za glukozo v krvi) po šestih mesecih zdravljenja.
It does this by blocking a protein in the kidneys (called SGLT2) that normally takes glucose back into the blood from the kidneys.
To doseže tako, da zavira beljakovino v ledvicah (imenovano SGLT2), ki običajno prenaša glukozo iz ledvic nazaj v kri.
Side effects reported with Steglujan are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Steglujan, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Steglujan is available as tablets in 2 strengths of ertugliflozin and sitagliptin (5 mg/100 mg and 15 mg/100 mg) and can only be obtained with a prescription.
Zdravilo Steglujan je na voljo v obliki tablet v dveh jakostih ertugliflozina in sitagliptina (5 mg/100 mg in 15 mg/100 mg), predpisovanje in izdaja zdravila pa je le na recept.
• patients whose blood glucose levels are not satisfactorily controlled with the diabetes medicines metformin and/or a sulphonylurea, in combination with either ertugliflozin or sitagliptin;
• pri bolnikih, pri katerih ravni glukoze v krvi ni mogoče zadostno uravnavati z zdraviloma za zdravljenje sladkorne bolezni, metforminom in/ali sulfonilsečnino v kombinaciji z ertugliflozinom ali sitagliptinom;
Sitagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon.
Sitagliptin prav tako zmanjša količino glukoze, ki jo tvorijo jetra, tako da poviša raven insulina in zniža raven hormona glukagona.
Type 2 diabetes is a disease in which the body does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Sladkorna bolezen tipa 2 je bolezen, pri kateri telo ne tvori dovolj insulina za uravnavanje ravni glukoze v krvi ali pri kateri ga telo ne more učinkovito izrabiti.
The recommended starting dose is one 5 mg/100 mg tablet taken once a day.
Priporočeni začetni odmerek je ena tableta v odmerku 5 mg/100 mg enkrat dnevno.
Sitagliptin blocks the breakdown of incretin hormones in the body.
Sitagliptin zavira razgradnjo inkretinskih hormonov v telesu.
These hormones stimulate the pancreas to produce insulin.
Ti hormoni stimulirajo trebušno slinavko k tvorbi insulina.
The second study found that adding ertugliflozin to a combination of sitagliptin and metformin was more effective than placebo (a dummy treatment).
V drugi študiji so ugotovili, da je dodajanje ertugliflozina kombinaciji sitagliptina in metformina učinkovitejše od placeba (zdravila brez zdravilne učinkovine).
Steglujan is a medicine used to control blood glucose (sugar) levels in adults with type 2 diabetes.
Steglujan je zdravilo, ki se uporablja za uravnavanje ravni glukoze (sladkorja) v krvi pri odraslih s sladkorno boleznijo tipa 2.
Treatment with Steglujan also led to weight loss, which is considered beneficial in patients with diabetes.
Zdravljenje z zdravilom Steglujan je privedlo tudi do zmanjšanja telesne mase, kar se pri bolnikih s sladkorno boleznijo šteje kot koristno.
The first study, in patients who were all taking metformin, compared the combination of ertugliflozin and sitagliptin with ertugliflozin or sitagliptin on their own.
V prvi študiji, opravljeni pri bolnikih, ki so vsi jemali metformin, so primerjali kombinacijo ertugliflozina in sitagliptina s samostojnim jemanjem ertugliflozina ali sitagliptina.
HbA1c levels fell by between 0.8 and 0.9 points, compared with a fall of 0.1 with placebo.
Ravni HvA1c so se znižale za od 0,8 do 0,9 odstotne točke, pri placebu pa za 0,1 odstotne točke.
The third study compared Steglujan with placebo in patients who were not taking other diabetes medicines and in whom diet and exercise were not enough to control their blood sugar levels.
V tretji študiji so zdravilo Steglujan primerjali s placebom pri bolnikih, ki niso jemali drugih zdravil za sladkorno bolezen in ki z dieto in telesno vadbo niso zadostno uravnavali krvnega sladkorja.
For the full list of side effects and restrictions with Steglujan, see the package leaflet.
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Steglujan glejte navodilo za uporabo.
How is Steglujan used?
Kako se zdravilo Steglujan uporablja?
Ertugliflozin helps to lower blood glucose by making the patient pass out glucose in the urine.
Ertugliflozin pomaga zniževati raven glukoze v krvi tako, da bolnik glukozo izloča v urin.
Treatment with the combination of ertugliflozin and sitagliptin lowered HbA1c levels by up to 1.5 percentage points, compared with reductions of up to 1.1 for ertugliflozin and for sitagliptin on their own.
Pri zdravljenju s kombinacijo ertugliflozina in sitagliptina so se ravni HbA1c znižale za do 1,5 odstotne točke, pri samem ertugliflozinu in sitagliptinu pa do 1,1 odstotne točke.
Other information about Steglujan
Druge informacije o zdravilu Steglujan
This study found that adding Steglujan to diet and exercise was much more effective than placebo, with HbA1c levels falling by between 1.6 and 1.7 points with the combination of ertugliflozin and sitagliptin compared with a fall of 0.4 points with placebo.
V tej študiji so ugotovili, da je zdravilo Steglujan kot dodatek dieti in telesni vadbi bistveno učinkovitejše od placeba, pri čemer so se ravni HbA1c pri kombinaciji ertugliflozina in sitagliptina znižale za od 1,6 do 1,7 odstotne točke, pri placebu pa za 0,4 odstotne točke.
Together, these actions reduce blood glucose levels and help to control type 2 diabetes.
Oba učinka skupaj znižata raven glukoze v krvi in prispevata k uravnavanju sladkorne bolezni tipa 2.
Prolonging the action of incretin hormones makes the pancreas produce more insulin when blood glucose levels are high.
S podaljšanjem delovanja inkretinskih hormonov spodbuja trebušno slinavko k tvorjenju večjih količin insulina, kadar so ravni glukoze v krvi visoke.
Steglujan contains the active substances ertugliflozin and sitagliptin.
Zdravilo Steglujan vsebuje zdravilni učinkovini ertugliflozin in sitagliptin.
The benefits of Steglujan were lower in patients with kidney problems.
Koristi zdravila Steglujan pri bolnikih s težavami z ledvicami so bile manjše.
Steglujan was shown to be effective at controlling blood glucose levels.
Zdravilo Steglujan se je izkazalo kot učinkovito pri uravnavanju koncentracije glukoze v krvi.
How does Steglujan work?
Kako zdravilo Steglujan deluje?
1 g / 0.5 g Powder for concentrate for solution for infusion
1 g/0,5 g prašek za koncentrat za raztopino za infundiranje intravenska uporaba viala (steklo) 10 vial
This does not rule out more direct countermeasures.
To ne izključuje neposrednejših protiukrepov.
You will not give yourself this medicine.
Tega zdravila si ne boste dali sami.
Appropriate measures should be taken to maintain stable arterial pressure.
Treba je izvesti ustrezne ukrepe za ohranjanje stabilnega arterijskega tlaka.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first utilisation: 25 June 2018
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 25 junij 2018
The single-dose applicator (SDA) must be discarded in accordance to the institutional policies and local requirements.
Aplikator z enkratnim odmerkom (SDA) je treba odstraniti skladno s politiko ustanove in lokalnimi zahtevami.
After receiving a dose you will not be given another dose for at least one hour.
Po prejemu odmerka ne boste dobili drugega odmerka najmanj eno uro.
Increased mortality was noted in all treatment groups.
Pri vseh tretiranih skupinah je bila opažena povečana umrljivost.
Dzuveo should not be used beyond 48 hours.
Zdravila Dzuveo se ne sme uporabljati dlje kot 48 ur.
In the case of an excessive dry mouth, patients may be given ice cubes.
V primeru čezmerno suhih ust se lahko bolnikom dajo ledene kocke.
Of the 221 patients, 147 received active treatment and 74 received placebo.
Od 221 bolnikov jih je 147 prejelo aktivno zdravljenje, 74 pa jih je prejelo placebo.
Hypnotic activity can be demonstrated by EEG alterations.
Hipnotično delovanje je mogoče dokazati s spremembami EEG.
Package leaflet: Information for the user
Navodilo za uporabo: informacije za uporabnika
Each pack contains either 5 or 10 pouches.
Vsako pakiranje vsebuje pet ali deset vrečk.
35, 80339 Munich, Germany.
35, 80339 München
tell your doctor if you are taking any of the following:
Zlasti povejte svojemu zdravniku, če jemljete kaj od naslednjega:
If you are having a blood test ensure your doctor knows you are taking this medicine.
Če vam bodo preiskali kri, poskrbite, da bo zdravnik vedel, da jemljete to zdravilo.
- Inability to pass urine.
- Nezmožnost odvajanja urina.
For sublingual use only.
Samo za sublingvalno uporabo.
Patients at higher risk are those with respiratory impairment or reduced respiratory reserve.
Bolniki z večjim tveganjem so tisti z okvaro dihal ali zmanjšano dihalno rezervo.
The expiry date refers to the last day of that month.
Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca;
Depending on individual sensitivity, the clinical picture is determined by the degree of respiratory depression.
Odvisno od občutljivosti posameznika klinično sliko določi stopnja depresije dihanja.
Primary attention should be given to obstruction of airways and the necessity of assisted or controlled ventilation.
Primarno pozornost je treba nameniti obstrukciji dihalnih poti in potrebi po asistiranem ali nadzorovanem predihavanju.
Dzuveo with alcohol
Dzuveo z alkoholom
In that case, the opioid antagonist can be administered repeatedly or by infusion.
V tem primeru se lahko opioidni antagonist da večkrat ali z infuzijo.
Caution should be exercised in patients on these concomitant medicinal products and they should be closely monitored.
Previdnost je potrebna pri bolnikih, ki jemljejo ta zdravila sočasno, in jih je treba skrbno spremljati.
Signs and symptoms
Znaki in simptomi:
Medicines should not be thrown away via wastewater or household waste.
Zdravila ne smete zavreči v odpadne vode ali med gospodinjske odpadke.
Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible, or when sufentanil is used in an emergency setting.
Zaradi teh tveganj mora biti sočasno predpisovanje teh pomirjeval pridržano za bolnike, pri katerih niso mogoče alternativne možnosti zdravljenja, ali kadar se sufentanil uporablja v nujnih primerih.
• The method of use of the device;
• postopkom za uporabo pripomočka;
Sufentanil does not induce histamine release.
Sufentanil ne inducira sproščanja histamina.
- Allergic reactions, itching of the skin.
- Alergijske reakcije, srbenje kože.
Email: edgar.fenzl@fgk-rs.de
20 E-poštni naslov:edgar.fenzl@fgk-rs.de
Rest the SDA lightly on the patient's teeth or lips.
Aplikator rahlo naslonite na bolnikove zobe ali ustnice.
Pharmacotherapeutic group: Anesthetics, opioid anesthetics, ATC Code: N01AH03.
Farmakoterapevtska skupina: Anestetiki, opioidni anestetiki, ATC-koda: N01AH03.
• The minimum dosing interval of one sublingual tablet per hour, in order to prevent / minimise the important identified risk of respiratory depression and the important potential risk of overdose;
• najkrajšim odmernim intervalom ene podjezične tablete na uro, da se prepreči/zmanjša pomembno ugotovljeno tveganje za depresijo dihanja in pomembno potencialno tveganje za preveliko odmerjanje;
Dzuveo is provided in a disposable single-dose applicator, to be administered by a healthcare provider as needed by the individual patient, but no more than once every hour, resulting in a maximum dose of 720 micrograms /day.
Zdravilo Dzuveo je na voljo v aplikatorju za enkratno uporabo z enkratnim odmerkom in ga mora dajati zdravstveni delavec, kakor je potrebno pri posameznem bolniku, vendar ne več kot enkrat na uro, s čimer je dosežen največji odmerek 720 mikrogramov/dan.
The applicator, with the tablet inside, is enclosed within a pouch.
Aplikator, v katerem je tableta, je zaprt v vrečki.